2855 GAZELLE COURT, CARLSBAD, CA
Reports Third Quarter 2025 Financial Results and Highlights Progress on Key Programs
Ionis reports positive results for zilganersen in Alexander disease, plans NDA by Q1 2026
Olezarsen Significantly Reduces Triglycerides and Acute Pancreatitis Events in Landmark Pivotal Studies for People with Severe Hypertriglyceridemia
Approved in the U.S. as First and Only RNA-Targeted Prophylactic Treatment for Hereditary Angioedema
Reports Second Quarter 2025 Financial Results and Highlights Progress on Key Programs
Dr. Richard Geary, Chief Development Officer to Retire; Dr. Holly Kordasiewicz to Assume Role in January 2026
Shareholder votes
Earnings Release
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Notice of Proposed Sale of Securities